Annual EBITDA:
$255.74M+$346.08M(+383.08%)Summary
- As of today, PTGX annual EBITDA is $255.74 million, with the most recent change of +$346.08 million (+383.08%) on December 31, 2024.
- During the last 3 years, PTGX annual EBITDA has risen by +$378.81 million (+307.80%).
- PTGX annual EBITDA is now at all-time high.
Performance
PTGX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$46.06M-$4.32M(-10.36%)Summary
- As of today, PTGX quarterly EBITDA is -$46.06 million, with the most recent change of -$4.32 million (-10.36%) on September 30, 2025.
- Over the past year, PTGX quarterly EBITDA has dropped by -$5.25 million (-12.88%).
- PTGX quarterly EBITDA is now -122.24% below its all-time high of $207.13 million, reached on March 31, 2024.
Performance
PTGX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$20.52M-$5.25M(-20.39%)Summary
- As of today, PTGX TTM EBITDA is $20.52 million, with the most recent change of -$5.25 million (-20.39%) on September 30, 2025.
- Over the past year, PTGX TTM EBITDA has dropped by -$131.79 million (-86.53%).
- PTGX TTM EBITDA is now -91.98% below its all-time high of $255.81 million, reached on December 31, 2024.
Performance
PTGX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PTGX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +383.1% | -12.9% | -86.5% |
| 3Y3 Years | +307.8% | -46.5% | +115.8% |
| 5Y5 Years | +440.1% | -518.6% | +133.2% |
PTGX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +299.8% | -122.2% | at low | -92.0% | +113.6% |
| 5Y | 5-Year | at high | +299.8% | -122.2% | at low | -92.0% | +113.6% |
| All-Time | All-Time | at high | +299.8% | -122.2% | at low | -92.0% | +113.6% |
PTGX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$46.06M(-10.4%) | $20.52M(-20.4%) |
| Jun 2025 | - | -$41.74M(-118.9%) | $25.77M(-13.0%) |
| Mar 2025 | - | -$19.07M(-115.0%) | $29.61M(-88.4%) |
| Dec 2024 | $255.74M(+383.1%) | $127.38M(+412.2%) | $255.81M(+68.0%) |
| Sep 2024 | - | -$40.81M(-7.7%) | $152.30M(-2.1%) |
| Jun 2024 | - | -$37.90M(-118.3%) | $155.61M(+2.4%) |
| Mar 2024 | - | $207.13M(+767.3%) | $151.98M(+268.2%) |
| Dec 2023 | -$90.34M(+29.4%) | $23.88M(+163.7%) | -$90.34M(+40.0%) |
| Sep 2023 | - | -$37.50M(+9.7%) | -$150.48M(-4.2%) |
| Jun 2023 | - | -$41.53M(-18.0%) | -$144.43M(-0.7%) |
| Mar 2023 | - | -$35.19M(+3.0%) | -$143.50M(-11.6%) |
| Dec 2022 | -$128.00M(-4.0%) | -$36.26M(-15.3%) | -$128.59M(+0.6%) |
| Sep 2022 | - | -$31.45M(+22.5%) | -$129.43M(+1.7%) |
| Jun 2022 | - | -$40.60M(-100.2%) | -$131.70M(-7.6%) |
| Mar 2022 | - | -$20.28M(+45.3%) | -$122.45M(+3.2%) |
| Dec 2021 | -$123.07M(-100.0%) | -$37.10M(-10.0%) | -$126.47M(-17.1%) |
| Sep 2021 | - | -$33.72M(-7.6%) | -$108.02M(-32.1%) |
| Jun 2021 | - | -$31.35M(-29.0%) | -$81.74M(-19.9%) |
| Mar 2021 | - | -$24.30M(-30.3%) | -$68.16M(-7.5%) |
| Dec 2020 | -$61.52M | -$18.64M(-150.4%) | -$63.40M(-2.5%) |
| Sep 2020 | - | -$7.45M(+58.1%) | -$61.85M(+14.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | -$17.77M(+9.0%) | -$71.98M(+17.7%) |
| Mar 2020 | - | -$19.54M(-14.3%) | -$87.49M(-5.3%) |
| Dec 2019 | -$75.19M(-91.8%) | -$17.10M(+2.7%) | -$83.11M(-2.2%) |
| Sep 2019 | - | -$17.57M(+47.2%) | -$81.29M(-11.4%) |
| Jun 2019 | - | -$33.29M(-119.8%) | -$72.96M(-49.7%) |
| Mar 2019 | - | -$15.15M(+0.9%) | -$48.74M(-16.8%) |
| Dec 2018 | -$39.20M(-7.2%) | -$15.28M(-65.4%) | -$41.74M(-39.8%) |
| Sep 2018 | - | -$9.24M(-1.9%) | -$29.85M(-17.1%) |
| Jun 2018 | - | -$9.07M(-11.3%) | -$25.49M(+19.0%) |
| Mar 2018 | - | -$8.15M(-140.0%) | -$31.46M(+16.1%) |
| Dec 2017 | -$36.55M(-13.0%) | -$3.40M(+30.3%) | -$37.49M(+17.5%) |
| Sep 2017 | - | -$4.87M(+67.6%) | -$45.42M(+4.6%) |
| Jun 2017 | - | -$15.04M(-6.0%) | -$47.60M(-20.3%) |
| Mar 2017 | - | -$14.19M(-25.3%) | -$39.57M(-22.3%) |
| Dec 2016 | -$32.35M(-122.4%) | -$11.32M(-60.5%) | -$32.35M(-53.8%) |
| Sep 2016 | - | -$7.05M(-0.7%) | -$21.03M(-50.5%) |
| Jun 2016 | - | -$7.00M(-0.5%) | -$13.97M(-100.5%) |
| Mar 2016 | - | -$6.97M(-164.8%) | -$6.97M(-164.8%) |
| Dec 2015 | -$14.55M(-60.5%) | - | - |
| Mar 2015 | - | -$2.63M | -$2.63M |
| Dec 2014 | -$9.06M | - | - |
FAQ
- What is Protagonist Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Protagonist Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Protagonist Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Protagonist Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of PTGX is $255.74M
What is the all-time high annual EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high annual EBITDA is $255.74M
What is Protagonist Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, PTGX annual EBITDA has changed by +$346.08M (+383.08%)
What is Protagonist Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of PTGX is -$46.06M
What is the all-time high quarterly EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high quarterly EBITDA is $207.13M
What is Protagonist Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, PTGX quarterly EBITDA has changed by -$5.25M (-12.88%)
What is Protagonist Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of PTGX is $20.52M
What is the all-time high TTM EBITDA for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high TTM EBITDA is $255.81M
What is Protagonist Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, PTGX TTM EBITDA has changed by -$131.79M (-86.53%)